O-35 serpinB3, a biomarker of taxane benefit in breast cancer
نویسندگان
چکیده
منابع مشابه
Taxane resistance in breast cancer
Despite recent progress in the treatment of breast cancer, disease recurrence remains a major issue to curative therapy. One of the major clinical issues is the development of drug resistance. Taxane resistance is a big challenge because taxanes, either alone or in combination, is the first-line regimens for treating breast cancer. A hierarchy of resistant mechanisms are responsible for taxane ...
متن کاملthe study of aaag repeat polymorphism in promoter of errg gene and its association with the risk of breast cancer in isfahan region
چکیده: سرطان پستان دومین عامل مرگ مرتبط با سرطان در خانم ها است. از آنجا که سرطان پستان یک تومور وابسته به هورمون است، می تواند توسط وضعیت هورمون های استروئیدی شامل استروژن و پروژسترون تنظیم شود. استروژن نقش مهمی در توسعه و پیشرفت سرطان پستان ایفا می کند و تاثیر خود را روی بیان ژن های هدف از طریق گیرنده های استروژن اعمال می کند. اما گروه دیگری از گیرنده های هسته ای به نام گیرنده های مرتبط به ا...
15 صفحه اولTaxane/anthracycline combinations: setting a new standard in breast cancer?
Among the novel chemotherapeutic drugs introduced in the 1990s, the taxanes have emerged as the most powerful compounds in breast cancer. Both compounds, paclitaxel and docetaxel, have been evaluated in metastatic settings before adjuvant trials proceeded. Docetaxel was shown in several phase III trials to be superior, particularly in terms of survival, for salvaging polychemotherapies after fa...
متن کاملBiomarker research in breast cancer.
Breast cancer is a heterogeneous disease with vast differences between patients regarding treatment response and prognosis. Therefore, strategies for individualizing care are needed. The rapid developments in biomarker research in breast cancer are making personalized breast cancer therapy a reality. A biomarker is defined as an objectively measured characteristic that can be evaluated as an in...
متن کاملGemcitabine-taxane experience in the treatment of metastatic breast cancer.
Management of metastatic breast cancer (MBC) is difficult and overall response rates (ORR) resulting from anthracycline and taxane-based regimens remain modest. The antimetabolite drug gemcitabine has been shown to have high activity when used as first-line treatment of MBC, particularly when incorporated into combined therapy regimens. Gemcitabine-containing regimens have also been used succes...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Cancer Supplements
سال: 2010
ISSN: 1359-6349
DOI: 10.1016/j.ejcsup.2010.06.036